HLA-B*58:01 Genotyping, Allopurinol Hypersensitivity

HLA-B*58:01 genotyping can be used to identify patients who are at increased risk for developing severe cutaneous adverse reactions (SCAR) after treatment with allopurinol, based on the presence of the HLA-B*58:01 allele. SCAR, also known as allopurinol hypersensitivity reaction, includes Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

### Disease Overview

The presence of the HLA-B*58:01 allele shows strong association with allopurinol-induced SCAR, including SJS and TEN.

### Prevalence and/or Incidence

HLA-B*58:01 allele frequency varies by ethnicity. The highest frequencies are found in Asian populations: up to 20% in Taiwan, Singapore, and among Han Chinese; 15.4% in India; 14.2% in Hong Kong; 12% in China and Korea; and 11% in Indonesia.

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Allele Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asians</td>
<td>5.3</td>
</tr>
<tr>
<td>African Americans</td>
<td>3.8</td>
</tr>
<tr>
<td>Native Hawaiians or Pacific Islanders</td>
<td>1.45</td>
</tr>
<tr>
<td>Hispanics</td>
<td>1.35</td>
</tr>
<tr>
<td>American Indians or Alaska Natives</td>
<td>1.19</td>
</tr>
<tr>
<td>Whites</td>
<td>0.8</td>
</tr>
</tbody>
</table>

### Symptoms

- Allopurinol is a major cause of SCAR, with an estimated risk of 0.1-0.4%.
- SCAR is manifested by SJS, TEN, or a drug reaction with eosinophilia, and systemic symptoms.
- Symptoms include rash combined with eosinophilia, leukocytosis, fever, hepatitis, and progressive kidney failure.
- Allopurinol-induced SCAR typically develops within weeks or a few months after initiation of treatment, and can be serious, with up to 25% mortality.

### Diagnostic Issues

- In addition to SCAR, a mild skin rash not associated with systemic symptoms or organ damage may develop in patients taking allopurinol.
  - These less severe rashes may occur in 2-3% of patients, and cannot be predicted by HLA-B*58:01 allele status.
- FDA guidelines recommend discontinuing allopurinol if a rash develops, regardless of allele status.
Screening/Detection

- Allopurinol is the most commonly used drug to treat hyperuricemia and gout. It inhibits xanthine oxidase, a key enzyme involved in uric acid formation.

- Due to the severity of allopurinol-induced SCAR, guidelines from the Clinical Pharmacogenomics Implementation Consortium (CPIC) recommend testing for the HLA-B*58:01 allele prior to initiation of therapy.

Genetics

Gene

HLA-B*58:01 allele

Inheritance

Codominant

Structure/Function

- The HLA-B*58:01 allele is located in the Class I HLA region, on human chromosome 6 (6p21.1-6p21.3).
- HLA-B58 encoded by the HLA-B*58:01 allele is expressed on the surface of all nucleated cells and has important immunological role in antigen presentation to T lymphocytes.

Test Interpretation

Sensitivity/Specificity

- Overall 50-60% sensitivity and ~90% specificity in pooled populations.
- Higher in populations with increased HLA-B*58:01 allele frequency
  - 90-100% sensitivity in Korean, Thai, Sardinia Italian, and Han Chinese populations.
- Low positive-predictive value (~1.5%), and high negative-predictive value for the HLA-B*58:01 allele, especially in patients of Asian descent (>99%).
- Analytical sensitivity/specificity is >99%.

Results

Positive

- HLA-B*58:01, heterozygous or homozygous, is detected.
- The presence of this allele increases risk for allopurinol-induced SCAR, including SJS or TEN.
  - Allopurinol treatment is contraindicated.
  - Alternative medication should be used as first-line therapy.
- Therapy should be discontinued immediately if symptoms of SJS or TEN develop.

Negative

- HLA-B*58:01 is not detected.
- The patient is not at risk for allopurinol-induced SCAR, including SJS or TEN.
  - Allopurinol can be used per standard dosing guidelines.
- Testing negative for HLA-B*58:01 does not totally eliminate the possibility of developing SCAR, especially in the White population with low-risk allele frequency.
- Allopurinol therapy should be discontinued in all patients if symptoms of SJS or TEN develop, regardless of HLA-B*58:01 status.

Limitations

- Copy number of HLA-B*58:01 will not be reported.
- Negative result for HLA-B*58:01 does not replace the need for therapeutic drug monitoring or other clinical testing.
- Other genetic and nongenetic factors that influence allopurinol-related adverse reactions are not evaluated.
Diagnostic errors can occur due to rare sequence variations, or the presence of rare and undocumented alleles.

Additional Resources


Related Information

Gout